Institutional portfolio tracker
Explore Viking Global's latest validated 13F portfolio and Hallucination Yield AI forecasts for covered positions.
Disclosed long book
$33.93 billion
Long positions
90
Calls / puts
0 / 0
Top 5 concentration
22.5%
Longs with AI data
17 / 90
Average AI 1Y
+15.9%
Monitored between quarterly reports
Schedules 13D and 13G can reveal a significant ownership event after a quarter closes. They are shown as a separate event timeline and never folded back into the 2026-06-30 Form 13F portfolio.
The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2026: 1,383,621 shares or share-equivalents representing 9.3% of the reported class. It was filed on August 14, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2026: 1,503,478 shares or share-equivalents representing 2.5% of the reported class. It was filed on August 14, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 9, 2026: 9,792,219 shares or share-equivalents representing 5% of the reported class. It was filed on July 10, 2026.
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Common Stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc. (the "Issuer"). The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. All share percentage calculations in this Amendment No. 12 to the Schedule 13D are based on 196,036,786 shares of Common Stock of the Issuer outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 6, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on June 12, 2026.
All share percentage calculations in this Schedule 13D are based on 390,368,119 shares of Common Stock outstanding as of May 4, 2026, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2026.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of May 11, 2026: 2,604,166 shares or share-equivalents representing 5.4% of the reported class. It was filed on May 18, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,461,633 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 2,666,690 shares or share-equivalents representing 5.3% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,482,434 shares or share-equivalents representing 5.03% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 1,690,555 shares or share-equivalents representing 4.5% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,653,310 shares or share-equivalents representing 5.6% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 29,993,708 shares or share-equivalents representing 18.8% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,195,181 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 8,264,607 shares or share-equivalents representing 7.8% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 35,824,562 shares or share-equivalents representing 16.2% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 58,651,170 shares or share-equivalents representing 15% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 22,479,388 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 528,954 shares or share-equivalents representing 9.99% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 0 shares or share-equivalents representing 0% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 3,577,128 shares or share-equivalents representing 7.1% of the reported class. It was filed on May 15, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 24, 2026: 13,400,000 shares or share-equivalents representing 6.7% of the reported class. It was filed on May 1, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 15, 2026: 1,815,350 shares or share-equivalents representing 5.2% of the reported class. It was filed on April 22, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2026: 11,842,434 shares or share-equivalents representing 6.1% of the reported class. It was filed on April 2, 2026.
All share percentage calculations in this Amendment No. 11 to the Schedule 13D are based on 193,862,871 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of February 12, 2026, as reported in the Issuer's annual report on Form 10-K filed with the Securities and Exchange Commission (the "Commission") on February 24, 2026.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 12, 2026: 13,026,367 shares or share-equivalents representing 6.8% of the reported class. It was filed on February 17, 2026.
All share percentage calculations in this Amendment No. 10 to the Schedule 13D are based on the difference between (i) 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025, and (ii) 1,081,825 shares of Common Stock that the Issuer repurchased on January 21, 2026, as reported in the Issuer's current report on Form 8-K filed with the Commission on January 21, 2026.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,222,969 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,454,608 shares or share-equivalents representing 9.99% of the reported class. It was filed on February 17, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 17, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 1,088,582 shares or share-equivalents representing 4.1% of the reported class. It was filed on February 17, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2025: 4,203,567 shares or share-equivalents representing 3.7% of the reported class. It was filed on February 17, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 5, 2026: 2,151,493 shares or share-equivalents representing 5.8% of the reported class. It was filed on February 12, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 6, 2026: 3,301,545 shares or share-equivalents representing 4.97% of the reported class. It was filed on January 13, 2026.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 18, 2025: 13,536,645 shares or share-equivalents representing 5.7% of the reported class. It was filed on December 30, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 5,128,875 shares or share-equivalents representing 4.2% of the reported class. It was filed on November 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 23,594,831 shares or share-equivalents representing 3.4% of the reported class. It was filed on November 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 3,123,262 shares or share-equivalents representing 4.7% of the reported class. It was filed on November 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 8,322,179 shares or share-equivalents representing 4.3% of the reported class. It was filed on November 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 30, 2025: 20,483,680 shares or share-equivalents representing 6.4% of the reported class. It was filed on November 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of November 14, 2025: 15,893,934 shares or share-equivalents representing 8.2% of the reported class. It was filed on November 14, 2025.
All share percentage calculations in this Amendment No. 9 to the Schedule 13D are based on 192,708,813 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of October 21, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on October 29, 2025.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 26, 2025: 3,482,434 shares or share-equivalents representing 5.1% of the reported class. It was filed on October 3, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 17, 2025: 2,666,690 shares or share-equivalents representing 5.5% of the reported class. It was filed on September 24, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of September 3, 2025: 1,337,356 shares or share-equivalents representing 5.02% of the reported class. It was filed on September 10, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of August 14, 2025: 17,780,183 shares or share-equivalents representing 9.3% of the reported class. It was filed on August 14, 2025.
All share percentage calculations in this Amendment No. 8 to the Schedule 13D are based on 191,168,504 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of July 29, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 5, 2025.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 7,505,694 shares or share-equivalents representing 5.9% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 11,537,518 shares or share-equivalents representing 2.8% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 8,729,345 shares or share-equivalents representing 9.99% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 3,430,128 shares or share-equivalents representing 5.2% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 12,288,611 shares or share-equivalents representing 6.4% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 30, 2025: 34,237,779 shares or share-equivalents representing 5.02% of the reported class. It was filed on August 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of July 17, 2025: 17,049,178 shares or share-equivalents representing 5.02% of the reported class. It was filed on July 24, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 27, 2025: 18,602,920 shares or share-equivalents representing 9.8% of the reported class. It was filed on July 1, 2025.
All share percentage calculations in this Amendment No. 7 to the Schedule 13D are based on 189,880,720 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of June 11, 2025: 19,602,116 shares or share-equivalents representing 5.3% of the reported class. It was filed on June 18, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 46,013,752 shares or share-equivalents representing 6.4% of the reported class. It was filed on May 15, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 6,572,700 shares or share-equivalents representing 9.2% of the reported class. It was filed on May 15, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 9,190,486 shares or share-equivalents representing 8.7% of the reported class. It was filed on May 15, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of March 31, 2025: 34,360,000 shares or share-equivalents representing 28.3% of the reported class. It was filed on May 15, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of April 11, 2025: 3,546,112 shares or share-equivalents representing 5.3% of the reported class. It was filed on April 18, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on March 12, 2025.
All share percentage calculations in this Amendment No. 6 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 1, 2024: 2,142,728 shares or share-equivalents representing 43.8% of the reported class. It was filed on March 12, 2025.
All share percentage calculations in this Amendment No. 13 to the Schedule 13D are based on 4,891,002 Ordinary Shares (as defined herein) expected to be outstanding after giving effect to each of the December 2023 Reverse Stock Split (as defined in Amendment No. 12) and the issuance of the New Shares (as defined in Amendment No. 12), as reported in the Issuer's current report on Form 6-K filed with the U.S. Securities and Exchange Commission (the "Commission") on December 7, 2023.
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of February 10, 2025: 2,952,754 shares or share-equivalents representing 6.7% of the reported class. It was filed on February 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 0 shares or share-equivalents representing 0% of the reported class. It was filed on February 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 6,978,534 shares or share-equivalents representing 6.5% of the reported class. It was filed on February 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of December 31, 2024: 21,537,518 shares or share-equivalents representing 7.8% of the reported class. It was filed on February 14, 2025.
See Item 4
Official SEC disclosure ↗The filing reports VIKING GLOBAL INVESTORS LP's beneficial ownership as of January 31, 2025: 22,055,375 shares or share-equivalents representing 11.7% of the reported class. It was filed on January 31, 2025.
All share percentage calculations in this Amendment No. 5 to the Schedule 13D are based on 188,989,802 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of November 5, 2024, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on November 12, 2024.
Official SEC disclosure ↗13F filing comparison
2026-03-31 to 2026-06-30
Newly reported
35
No longer reported
22
Increased
18
Reduced
27
Present now and absent from the immediately preceding comparable filing.
| Position | Kind | Shares | Value |
|---|---|---|---|
FERRARI N V FERRARI N V | LONG | 2,204,309 | $816.9 million |
MSCI INC MSCI INC | LONG | 1,160,687 | $650.0 million |
UNION PAC CORP UNION PAC CORP | LONG | 2,047,332 | $556.9 million |
DIGITAL RLTY TR INC DIGITAL RLTY TR INC | LONG | 2,310,475 | $414.9 million |
CARNIVAL CORP LTD CARNIVAL CORP LTD | LONG | 14,299,953 | $408.5 million |
CVS HEALTH CORP CVS HEALTH CORP | LONG | 3,663,361 | $379.0 million |
FEDEX FGHT HLDG CO INC FEDEX FGHT HLDG CO INC | LONG | 2,366,634 | $357.4 million |
MORGAN STANLEY MORGAN STANLEY | LONG | 1,622,593 | $339.2 million |
QCOM QUALCOMM INC | LONG | 1,514,185 | $279.8 million |
APTIV PLC APTIV PLC | LONG | 4,552,887 | $279.5 million |
AVALONBAY CMNTYS INC AVALONBAY CMNTYS INC | LONG | 1,339,782 | $252.8 million |
SNOW SNOWFLAKE INC | LONG | 960,138 | $244.4 million |
EQUITABLE HLDGS INC EQUITABLE HLDGS INC | LONG | 5,398,896 | $236.9 million |
TAKE-TWO INTERACTIVE SOFTWAR TAKE-TWO INTERACTIVE SOFTWAR | LONG | 940,605 | $235.1 million |
SPACE EXPLORATION TECHN CORP SPACE EXPLORATION TECHN CORP | LONG | 1,200,000 | $205.0 million |
BCE INC BCE INC | LONG | 8,383,278 | $180.6 million |
US FOODS HLDG CORP US FOODS HLDG CORP | LONG | 1,734,346 | $177.3 million |
UBS GROUP AG UBS GROUP AG | LONG | 2,435,805 | $120.8 million |
BRIGHTSPRING HEALTH SVCS INC BRIGHTSPRING HEALTH SVCS INC | LONG | 1,618,237 | $112.9 million |
NTRA NATERA INC | LONG | 390,694 | $106.1 million |
DEUTSCHE BK AG DEUTSCHE BK AG | LONG | 2,510,554 | $85.0 million |
COREBRIDGE FINL INC COREBRIDGE FINL INC | LONG | 2,679,371 | $76.7 million |
SOLAREDGE TECHNOLOGIES INC SOLAREDGE TECHNOLOGIES INC | LONG | 1,088,469 | $63.6 million |
BRUKER CORP BRUKER CORP | LONG | 893,491 | $53.8 million |
CME GROUP INC CME GROUP INC | LONG | 152,980 | $33.8 million |
TRADEWEB MKTS INC TRADEWEB MKTS INC | LONG | 314,222 | $31.3 million |
INFLEQTION INC INFLEQTION INC | LONG | 2,032,649 | $27.1 million |
ARTIVA BIOTHERAPEUTICS INC ARTIVA BIOTHERAPEUTICS INC | LONG | 2,604,166 | $25.3 million |
QUANTINUUM INC QUANTINUUM INC | LONG | 306,123 | $25.0 million |
FERVO ENERGY CO FERVO ENERGY CO | LONG | 750,000 | $21.9 million |
ALTIMMUNE INC ALTIMMUNE INC | LONG | 6,700,000 | $20.4 million |
TOLL BROTHERS INC TOLL BROTHERS INC | LONG | 109,856 | $18.1 million |
DPC HOLDINGS PLC DPC HOLDINGS PLC | LONG | 306,123 | $15.0 million |
X-ENERGY INC X-ENERGY INC | LONG | 714,286 | $13.1 million |
AZUL S A AZUL S A | LONG | 1,349,734 | $12.1 million |
Present in the prior comparable filing and absent from this one.
| Position | Kind | Prior shares | Prior value |
|---|---|---|---|
GOOGL ALPHABET INC · CAP STK CL A | LONG | 2,395,865 | $689.0 million |
AMERICAN INTL GROUP INC AMERICAN INTL GROUP INC · COM NEW | LONG | 4,221,223 | $317.6 million |
API GROUP CORP API GROUP CORP · COM STK | LONG | 5,837,000 | $236.5 million |
APPLE INC APPLE INC · COM | LONG | 3,593,057 | $911.9 million |
CARNIVAL CORP CARNIVAL CORP · COMMON STOCK | LONG | 13,721,348 | $355.1 million |
CBOE GLOBAL MKTS INC CBOE GLOBAL MKTS INC · COM | LONG | 688,417 | $193.5 million |
CELESTICA INC CELESTICA INC · COM | LONG | 1,654,989 | $466.2 million |
CRWV COREWEAVE INC · COM CL A | LONG | 1,397,438 | $108.3 million |
CSX CORP CSX CORP · COM | LONG | 18,678,052 | $766.7 million |
EDWARDS LIFESCIENCES CORP EDWARDS LIFESCIENCES CORP · COM | LONG | 1,097,578 | $87.9 million |
EQPT EQUIPMENTSHARE COM INC · COM CL A | LONG | 1,000,000 | $20.4 million |
FORGENT POWER SOLUTIONS INC FORGENT POWER SOLUTIONS INC · COM SHS CL A | LONG | 650,000 | $19.0 million |
GALLAGHER ARTHUR J & CO GALLAGHER ARTHUR J & CO · COM | LONG | 727,441 | $157.5 million |
HCA HEALTHCARE INC HCA HEALTHCARE INC · COM | LONG | 1,075,133 | $508.8 million |
LULULEMON ATHLETICA INC LULULEMON ATHLETICA INC · COM | LONG | 980,568 | $150.1 million |
PNC FINL SVCS GROUP INC PNC FINL SVCS GROUP INC · COM | LONG | 3,027,092 | $629.9 million |
PROGRESSIVE CORP PROGRESSIVE CORP · COM | LONG | 1,616,559 | $320.5 million |
RALLIANT CORP RALLIANT CORP · COM | LONG | 2,134,899 | $88.8 million |
STELLANTIS N.V STELLANTIS N.V · SHS | LONG | 15,980,268 | $111.9 million |
T-MOBILE US INC T-MOBILE US INC · COM | LONG | 2,967,374 | $623.2 million |
TWLO TWILIO INC · CL A | LONG | 450,770 | $56.7 million |
WEST PHARMACEUTICAL SVSC INC WEST PHARMACEUTICAL SVSC INC · COM | LONG | 416,948 | $104.5 million |
“No longer reported” means the position is absent from this comparable 13F filing. It does not prove the manager sold it: reporting thresholds, confidential treatment, corporate actions, or instrument changes can also explain the omission.
| Position | Kind | Shares | Value | Long weight | Quarter change | AI at filing · 1Y | AI now |
|---|---|---|---|---|---|---|---|
V Visa Inc. | LONG | 6,393,604 | $2.19 billion | 6.5% | INCREASED | — | 1Y — 5Y — |
TSM Taiwan Semiconductor Manufacturing Co. | LONG | 3,168,097 | $1.51 billion | 4.5% | REDUCED | 24.3% | 1Y +23.9% 5Y +141.4% · 7 models |
AIR PRODUCTS AND CHEMICALS I AIR PRODUCTS AND CHEMICALS I · COM · 009158106 | LONG | 4,740,351 | $1.39 billion | 4.1% | INCREASED | — | 1Y — 5Y — |
SHW Sherwin-Williams | LONG | 3,875,879 | $1.33 billion | 3.9% | INCREASED | — | 1Y — 5Y — |
FTV Fortive | LONG | 19,934,762 | $1.22 billion | 3.6% | REDUCED | — | 1Y — 5Y — |
META Meta Platforms Inc. | LONG | 1,867,619 | $1.05 billion | 3.1% | INCREASED | 22.1% | 1Y +18.1% 5Y +104.6% · 8 models |
SCHW Charles Schwab Corporation | LONG | 10,638,869 | $981.6 million | 2.9% | REDUCED | 16.6% | 1Y +15.7% 5Y +72.0% · 7 models |
TMO Thermo Fisher Scientific Inc. | LONG | 1,937,415 | $971.3 million | 2.9% | INCREASED | 12.3% | 1Y +13.1% 5Y +68.9% · 7 models |
JPM JPMorgan Chase & Co. | LONG | 2,899,386 | $949.1 million | 2.8% | INCREASED | 12.9% | 1Y +11.9% 5Y +62.5% · 8 models |
LENNOX INTL INC LENNOX INTL INC · COM · 526107107 | LONG | 1,590,959 | $911.5 million | 2.7% | INCREASED | — | 1Y — 5Y — |
AMZN Amazon.com Inc. | LONG | 3,700,862 | $882.1 million | 2.6% | INCREASED | 22.4% | 1Y +19.4% 5Y +96.9% · 8 models |
FERRARI N V FERRARI N V · COM · N3167Y103 | LONG | 2,204,309 | $816.9 million | 2.4% | NEWLY REPORTED | — | 1Y — 5Y — |
CVNA CARVANA CO · CL A · 146869102 | LONG | 12,322,311 | $811.1 million | 2.4% | INCREASED | — | 1Y — 5Y — |
MCD McDonald's Corp. | LONG | 2,829,158 | $764.7 million | 2.3% | REDUCED | 9.7% | 1Y +8.9% 5Y +51.6% · 5 models |
BRIDGEBIO PHARMA INC BRIDGEBIO PHARMA INC · COM · 10806X102 | LONG | 9,949,219 | $741.0 million | 2.2% | REDUCED | — | 1Y — 5Y — |
BA Boeing Co. | LONG | 3,274,825 | $708.9 million | 2.1% | INCREASED | 19.0% | 1Y +16.1% 5Y +75.9% · 8 models |
MAA Mid-America Apartments | LONG | 5,043,318 | $700.7 million | 2.1% | INCREASED | — | 1Y — 5Y — |
DIS Walt Disney Co. | LONG | 7,158,406 | $689.0 million | 2.0% | REDUCED | 14.7% | 1Y +12.4% 5Y +60.9% · 6 models |
FDX FedEx | LONG | 2,151,983 | $673.9 million | 2.0% | INCREASED | — | 1Y — 5Y — |
MSCI INC MSCI INC · COM · 55354G100 | LONG | 1,160,687 | $650.0 million | 1.9% | NEWLY REPORTED | — | 1Y — 5Y — |
ADAPTIVE BIOTECHNOLOGIES COR ADAPTIVE BIOTECHNOLOGIES COR · COM · 00650F109 | LONG | 29,993,708 | $643.4 million | 1.9% | UNCHANGED | — | 1Y — 5Y — |
WAT Waters Corporation | LONG | 1,662,140 | $623.4 million | 1.8% | INCREASED | 11.2% | 1Y +11.8% 5Y +55.9% · 7 models |
JCI Johnson Controls | LONG | 4,202,694 | $614.1 million | 1.8% | REDUCED | — | 1Y — 5Y — |
UNION PAC CORP UNION PAC CORP · COM · 907818108 | LONG | 2,047,332 | $556.9 million | 1.6% | NEWLY REPORTED | — | 1Y — 5Y — |
MSFT Microsoft Corporation | LONG | 1,458,618 | $544.1 million | 1.6% | REDUCED | 16.6% | 1Y +14.2% 5Y +78.3% · 6 models |
SEA LTD SEA LTD · SPONSORD ADS · 81141R100 | LONG | 5,669,877 | $543.3 million | — | INCREASED | — | 1Y — 5Y — |
CAMDEN PPTY TR CAMDEN PPTY TR · SH BEN INT · 133131102 | LONG | 4,513,303 | $516.7 million | — | REDUCED | — | 1Y — 5Y — |
REGAL REXNORD CORPORATION REGAL REXNORD CORPORATION · COM · 758750103 | LONG | 2,101,759 | $500.6 million | 1.5% | REDUCED | — | 1Y — 5Y — |
BIOMARIN PHARMACEUTICAL INC BIOMARIN PHARMACEUTICAL INC · COM · 09061G101 | LONG | 7,616,563 | $435.8 million | 1.3% | INCREASED | — | 1Y — 5Y — |
INTERACTIVE BROKERS GROUP IN INTERACTIVE BROKERS GROUP IN · COM CL A · 45841N107 | LONG | 4,830,748 | $420.5 million | 1.2% | INCREASED | — | 1Y — 5Y — |
DIGITAL RLTY TR INC DIGITAL RLTY TR INC · COM · 253868103 | LONG | 2,310,475 | $414.9 million | 1.2% | NEWLY REPORTED | — | 1Y — 5Y — |
CARNIVAL CORP LTD CARNIVAL CORP LTD · COMMON SHARES · G2004J103 | LONG | 14,299,953 | $408.5 million | 1.2% | NEWLY REPORTED | — | 1Y — 5Y — |
GM General Motors | LONG | 5,005,833 | $385.8 million | 1.1% | REDUCED | — | 1Y — 5Y — |
AON Aon plc | LONG | 1,151,269 | $381.9 million | 1.1% | INCREASED | — | 1Y — 5Y — |
CVS HEALTH CORP CVS HEALTH CORP · COM · 126650100 | LONG | 3,663,361 | $379.0 million | 1.1% | NEWLY REPORTED | — | 1Y — 5Y — |
FEDEX FGHT HLDG CO INC FEDEX FGHT HLDG CO INC · COMMON STOCK · 314352105 | LONG | 2,366,634 | $357.4 million | 1.1% | NEWLY REPORTED | — | 1Y — 5Y — |
ICE Intercontinental Exchange | LONG | 2,777,138 | $341.9 million | 1.0% | REDUCED | — | 1Y — 5Y — |
MORGAN STANLEY MORGAN STANLEY · COM NEW · 617446448 | LONG | 1,622,593 | $339.2 million | 1.0% | NEWLY REPORTED | — | 1Y — 5Y — |
HD Home Depot Inc. | LONG | 920,595 | $324.7 million | 1.0% | INCREASED | 10.5% | 1Y +10.1% 5Y +57.1% · 7 models |
TIC SOLUTIONS INC TIC SOLUTIONS INC · COM · 00510N102 | LONG | 35,824,562 | $289.8 million | 0.9% | UNCHANGED | — | 1Y — 5Y — |
QCOM Qualcomm Inc. | LONG | 1,514,185 | $279.8 million | 0.8% | NEWLY REPORTED | 20.3% | 1Y +15.6% 5Y +79.0% · 5 models |
APTIV PLC APTIV PLC · COM SHS · G3265R107 | LONG | 4,552,887 | $279.5 million | 0.8% | NEWLY REPORTED | — | 1Y — 5Y — |
RDDT Reddit Inc. | LONG | 1,565,518 | $271.7 million | 0.8% | REDUCED | 29.1% | 1Y +25.4% 5Y +142.0% · 5 models |
HAS Hasbro | LONG | 3,107,195 | $256.6 million | 0.8% | REDUCED | — | 1Y — 5Y — |
AVALONBAY CMNTYS INC AVALONBAY CMNTYS INC · COM · 053484101 | LONG | 1,339,782 | $252.8 million | 0.7% | NEWLY REPORTED | — | 1Y — 5Y — |
DKS DICKS SPORTING GOODS INC · COM · 253393102 | LONG | 1,106,134 | $250.9 million | 0.7% | REDUCED | — | 1Y — 5Y — |
SNOW Snowflake Inc. | LONG | 960,138 | $244.4 million | 0.7% | NEWLY REPORTED | 20.6% | 1Y +17.2% 5Y +102.0% · 5 models |
EQUITABLE HLDGS INC EQUITABLE HLDGS INC · COM · 29452E101 | LONG | 5,398,896 | $236.9 million | 0.7% | NEWLY REPORTED | — | 1Y — 5Y — |
TAKE-TWO INTERACTIVE SOFTWAR TAKE-TWO INTERACTIVE SOFTWAR · COM · 874054109 | LONG | 940,605 | $235.1 million | 0.7% | NEWLY REPORTED | — | 1Y — 5Y — |
TSLA Tesla Inc. | LONG | 547,816 | $230.4 million | 0.7% | REDUCED | 21.0% | 1Y +11.3% 5Y +86.9% · 8 models |
ATI INC ATI INC · COM · 01741R102 | LONG | 1,153,880 | $227.4 million | 0.7% | REDUCED | — | 1Y — 5Y — |
ROIV Roivant Sciences Ltd | LONG | 6,271,467 | $221.9 million | 0.7% | REDUCED | 31.6% | 1Y +25.7% 5Y +126.7% · 6 models |
SPACE EXPLORATION TECHN CORP SPACE EXPLORATION TECHN CORP · CLASS A COM STK · 84615Q103 | LONG | 1,200,000 | $205.0 million | 0.6% | NEWLY REPORTED | — | 1Y — 5Y — |
AMER SPORTS INC AMER SPORTS INC · COM SHS · G0260P102 | LONG | 5,954,351 | $201.5 million | 0.6% | REDUCED | — | 1Y — 5Y — |
VERADERMICS INC VERADERMICS INC · COMMON STOCK · 922967104 | LONG | 1,561,494 | $192.0 million | 0.6% | REDUCED | — | 1Y — 5Y — |
MEDLINE INC MEDLINE INC · COM CL A · 58507V107 | LONG | 4,841,080 | $190.9 million | 0.6% | REDUCED | — | 1Y — 5Y — |
BCE INC BCE INC · COM NEW · 05534B760 | LONG | 8,383,278 | $180.6 million | 0.5% | NEWLY REPORTED | — | 1Y — 5Y — |
US FOODS HLDG CORP US FOODS HLDG CORP · COM · 912008109 | LONG | 1,734,346 | $177.3 million | 0.5% | NEWLY REPORTED | — | 1Y — 5Y — |
ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC · COM · 687604108 | LONG | 1,503,478 | $143.1 million | 0.4% | REDUCED | — | 1Y — 5Y — |
NEWAMSTERDAM PHARMA COMPANY NEWAMSTERDAM PHARMA COMPANY · ORDINARY SHARES · N62509109 | LONG | 4,203,567 | $142.5 million | 0.4% | UNCHANGED | — | 1Y — 5Y — |
SIONNA THERAPEUTICS INC SIONNA THERAPEUTICS INC · COM · 829401108 | LONG | 3,195,181 | $140.6 million | 0.4% | UNCHANGED | — | 1Y — 5Y — |
CHUBB LIMITED CHUBB LIMITED · COM · H1467J104 | LONG | 377,312 | $128.6 million | 0.4% | REDUCED | — | 1Y — 5Y — |
PHARVARIS N V PHARVARIS N V · COM · N69605108 | LONG | 3,653,310 | $126.3 million | 0.4% | UNCHANGED | — | 1Y — 5Y — |
UBS GROUP AG UBS GROUP AG · SHS · H42097107 | LONG | 2,435,805 | $120.8 million | 0.4% | NEWLY REPORTED | — | 1Y — 5Y — |
BRIGHTSPRING HEALTH SVCS INC BRIGHTSPRING HEALTH SVCS INC · COM · 10950A106 | LONG | 1,618,237 | $112.9 million | 0.3% | NEWLY REPORTED | — | 1Y — 5Y — |
INHIBRX BIOSCIENCES INC INHIBRX BIOSCIENCES INC · COM · 45720N103 | LONG | 1,123,929 | $106.5 million | 0.3% | REDUCED | — | 1Y — 5Y — |
NTRA NATERA INC · COM · 632307104 | LONG | 390,694 | $106.1 million | 0.3% | NEWLY REPORTED | — | 1Y — 5Y — |
DEUTSCHE BK AG DEUTSCHE BK AG · NAMEN AKT · D18190898 | LONG | 2,510,554 | $85.0 million | — | NEWLY REPORTED | — | 1Y — 5Y — |
CAPITAL ONE FINL CORP CAPITAL ONE FINL CORP · COM · 14040H105 | LONG | 387,815 | $77.8 million | 0.2% | REDUCED | — | 1Y — 5Y — |
COREBRIDGE FINL INC COREBRIDGE FINL INC · COM · 21871X109 | LONG | 2,679,371 | $76.7 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
SOLAREDGE TECHNOLOGIES INC SOLAREDGE TECHNOLOGIES INC · COM · 83417M104 | LONG | 1,088,469 | $63.6 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
DAMORA THERAPEUTICS INC DAMORA THERAPEUTICS INC · COM NEW · 36322Q206 | LONG | 2,311,082 | $60.1 million | 0.2% | UNCHANGED | — | 1Y — 5Y — |
ORIC PHARMACEUTICALS INC ORIC PHARMACEUTICALS INC · COM · 68622P109 | LONG | 5,126,762 | $55.5 million | 0.2% | REDUCED | — | 1Y — 5Y — |
BRUKER CORP BRUKER CORP · COM · 116794108 | LONG | 893,491 | $53.8 million | 0.2% | NEWLY REPORTED | — | 1Y — 5Y — |
STANDARD BIOTOOLS INC STANDARD BIOTOOLS INC · COM · 34385P108 | LONG | 58,651,170 | $48.3 million | 0.1% | UNCHANGED | — | 1Y — 5Y — |
GINKGO BIOWORKS HOLDINGS INC GINKGO BIOWORKS HOLDINGS INC · CL A NEW · 37611X209 | LONG | 3,577,128 | $35.4 million | 0.1% | UNCHANGED | — | 1Y — 5Y — |
CME GROUP INC CME GROUP INC · COM · 12572Q105 | LONG | 152,980 | $33.8 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
TRADEWEB MKTS INC TRADEWEB MKTS INC · CL A · 892672106 | LONG | 314,222 | $31.3 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
TREVI THERAPEUTICS INC TREVI THERAPEUTICS INC · COM · 89532M101 | LONG | 1,544,644 | $28.8 million | 0.1% | REDUCED | — | 1Y — 5Y — |
INFLEQTION INC INFLEQTION INC · COM SHS · 45676K103 | LONG | 2,032,649 | $27.1 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
ARTIVA BIOTHERAPEUTICS INC ARTIVA BIOTHERAPEUTICS INC · COM · 04317A107 | LONG | 2,604,166 | $25.3 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
QUANTINUUM INC QUANTINUUM INC · CL A COM · 74768A104 | LONG | 306,123 | $25.0 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
FERVO ENERGY CO FERVO ENERGY CO · CL A COM · 31556C106 | LONG | 750,000 | $21.9 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
ALTIMMUNE INC ALTIMMUNE INC · COM NEW · 02155H200 | LONG | 6,700,000 | $20.4 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
TOLL BROTHERS INC TOLL BROTHERS INC · COM · 889478103 | LONG | 109,856 | $18.1 million | 0.1% | NEWLY REPORTED | — | 1Y — 5Y — |
DPC HOLDINGS PLC DPC HOLDINGS PLC · ORDINARY SHARES · G2R11M108 | LONG | 306,123 | $15.0 million | 0.0% | NEWLY REPORTED | — | 1Y — 5Y — |
X-ENERGY INC X-ENERGY INC · COM CL A · 98386P102 | LONG | 714,286 | $13.1 million | 0.0% | NEWLY REPORTED | — | 1Y — 5Y — |
AZUL S A AZUL S A · SPONSORED ADS · 05501U601 | LONG | 1,349,734 | $12.1 million | 0.0% | NEWLY REPORTED | — | 1Y — 5Y — |
RALLYBIO CORP RALLYBIO CORP · COM · 75120L209 | LONG | 524,347 | $8.4 million | 0.0% | UNCHANGED | — | 1Y — 5Y — |
PEPGEN INC PEPGEN INC · COM · 713317105 | LONG | 3,482,434 | $6.3 million | 0.0% | UNCHANGED | — | 1Y — 5Y — |
Every filing event remains separate, including notices and amendments. Open a holdings date for the canonical portfolio through its latest filing, or an accession for the exact source event.